You are viewing the site in preview mode

Skip to main content

Table 3 Bone formation and resorption markers. Bone Alkaline Phosphate (BALP) and Deoxypyridinoline (DPD) level in patients with established osteoporosis compared between Alendronate group (ALN) (n = 22) and placebo control group (CON) (n = 25) at baseline and follow-up at 6- and 12 months (Data: mean ± SD)

From: Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis

Biochemical Markers Group Baseline 6-month 12-month % difference+
BALP ALN 62.27 ± 16.86 40.33 ± 9.98 ** 34.35 ± 9.87 ** -39.9 ± 33.6a
  CON 66.17 ± 14.91 56.72 ± 18.24 ** 55.13 ± 15.76 ** -16.7 ± 14.5
DPD ALN 50.82 ± 35.10 25.11 ± 18.65 ** 23.03 ± 14.72 ** -42.6 ± 30.4b
  CON 33.70 ± 20.28 40.11 ± 36.92 27.28 ± 10.95 -9.4 ± 26.7
  1. +: percentage difference compared between baseline and 12-month
  2. a: p < 0.01; b: p < 0.05: significant difference in BALP found between ALN and CON group (independent t-test)
  3. *p < 0.05; ** p < 0.01: compared with baseline (paired t-test)
Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X